- Home
- EVOK vs ACXP Comparison
EVOK vs ACXP Comparison
Compare EVOK & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- ACXP
- Stock Information
- Founded
- EVOK 2007
- ACXP 2017
- Country
- EVOK United States
- ACXP United States
- Employees
- EVOK N/A
- ACXP N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- ACXP Health Care
- Exchange
- EVOK Nasdaq
- ACXP Nasdaq
- Market Cap
- EVOK 7.6M
- ACXP 6.8M
- IPO Year
- EVOK 2013
- ACXP 2021
- Fundamental
- Price
- EVOK $5.15
- ACXP $5.02
- Analyst Decision
- EVOK
- ACXP Strong Buy
- Analyst Count
- EVOK 0
- ACXP 3
- Target Price
- EVOK N/A
- ACXP $143.67
- AVG Volume (30 Days)
- EVOK 26.0K
- ACXP 1.7M
- Earning Date
- EVOK 11-07-2025
- ACXP 11-12-2025
- Dividend Yield
- EVOK N/A
- ACXP N/A
- EPS Growth
- EVOK N/A
- ACXP N/A
- EPS
- EVOK N/A
- ACXP N/A
- Revenue
- EVOK $12,794,859.00
- ACXP N/A
- Revenue This Year
- EVOK $57.38
- ACXP N/A
- Revenue Next Year
- EVOK $59.57
- ACXP N/A
- P/E Ratio
- EVOK N/A
- ACXP N/A
- Revenue Growth
- EVOK 70.02
- ACXP N/A
- 52 Week Low
- EVOK $1.94
- ACXP $3.80
- 52 Week High
- EVOK $9.88
- ACXP $38.57
- Technical
- Relative Strength Index (RSI)
- EVOK 57.04
- ACXP 39.26
- Support Level
- EVOK $4.53
- ACXP $6.24
- Resistance Level
- EVOK $5.19
- ACXP $6.80
- Average True Range (ATR)
- EVOK 0.28
- ACXP 0.53
- MACD
- EVOK 0.07
- ACXP -0.30
- Stochastic Oscillator
- EVOK 91.26
- ACXP 3.72
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.